ARCHIVES

Cancer Patient Lobby Outlines Agenda For FDA Reform, Seeks Role In Discussion

This article is from The Cancer Letter archive.

Vol. 21 No. 25 | June 23, 1995

Download PDF Visit The Full Archive

Related Articles

Conversation With The Cancer Letter: How ASCO’s Guideline Differs—And Why

July 20, 2012

The Selling Begins: CT Offered Beyond High-Risk Group

November 26, 2010

Francis Collins Nominated For NIH Director Two Days After Final Stem Cell Guidelines Released.

July 10, 2009

Dear FDA: Provenge Provokes Letters From Opponents, Advocates, Investors.

April 27, 2007

ET2 Meber discusses Grants Funding Issue, Says Problem Is Money

July 23, 1993

After Furlough, Blizzard, NCI Struggles to Clear Backlog and Resume Business

January 19, 1996